Abril Ivett Priscilla Gómez-Guzman

Dr. Abril Ivett Priscilla Gómez-Guzman

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Miguel Angel Robles-GarcíaMiguel Angel Robles-García
Miguel Angel Robles-García
CDCarmen Lizette Del-Toro-Sánchez
Carmen Lizette Del-Toro-Sánchez
GLGermán Limón-Vargas
Germán Limón-Vargas
Melesio Gutiérrez-LomelíMelesio Gutiérrez-Lomelí
Melesio Gutiérrez-Lomelí
MNMaria Guadalupe Avila Novoa
Maria Guadalupe Avila Novoa
RVRicardo Vega
Ricardo Vega
In pursuing functional foods that promote health, nanoliposomal carriers have been used to enhance the stability and functionality of dairy products such as yogurt, promising therapeutic benefits. This study aimed to evaluate the impact of fucoxanthin-loaded nanoliposomes in yogurt on its antioxidant, physicochemical, and rheological properties under cold storage (21 days). Fucoxanthin-loaded nanoliposomes were prepared using the ultrasonic film dispersion technique and added at concentrations of 0%, 5%, and 10% in the yogurt (Y-C, Y-FXN-5, Y-FXN-10). Homogeneous and uniform nanoliposomes (98.28 nm) were obtained, preserving their integrity and functionality and ensuring the prolonged release and bioavailability of fucoxanthin. Y-FXN-10 maintained the highest antioxidant activity according to the DPPH (52.96%), ABTS (97.97%), and FRAP (3.16 mmol ET/g) methods. This formulation exhibited enhanced erythroprotective potential, inhibiting hemolysis, photohemolysis, and heat-induced hemolysis. However, viscosity and firmness decreased, affecting the texture and appearance. Sensory properties such as the color, flavor, aftertaste, texture, and overall acceptance improved with the 10% fucoxanthin-enriched yogurt formulation. These results suggest that nanoliposomes are suitable for carrying fucoxanthin. Their incorporation into food matrices is critical to developing functional foods. Regulatory approvals and consumer perceptions regarding nanotechnology-based products must be addressed, emphasizing their safety and health benefits.

24 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Miguel Angel Robles-GarcíaMiguel Angel Robles-García
Miguel Angel Robles-García
CDCarmen Lizette Del-Toro-Sánchez
Carmen Lizette Del-Toro-Sánchez
GLGermán Limón-Vargas
Germán Limón-Vargas
Melesio Gutiérrez-LomelíMelesio Gutiérrez-Lomelí
Melesio Gutiérrez-Lomelí
MNMaria Guadalupe Avila Novoa
Maria Guadalupe Avila Novoa
RVRicardo Vega
Ricardo Vega
In pursuing functional foods that promote health, nanoliposomal carriers have been used to enhance the stability and functionality of dairy products such as yogurt, promising therapeutic benefits. This study aimed to evaluate the impact of fucoxanthin-loaded nanoliposomes in yogurt on its antioxidant, physico-chemical, and rheological properties under cold storage (21 days). Fucoxanthin-loaded nanoliposomes were prepared using the ultrasonic film dispersion technique and added at concentrations of 0%, 5%, and 10% in the yogurt (Y-C, Y-FXN-5, Y-FXN-10). Homogeneous and uniform nanoliposomes (98.28 nm) were ob-tained, preserving their integrity and functionality and ensuring prolonged release and bioavailability of fucoxanthin. Y-FXN-10 maintained the highest antioxidant activity according to the DPPH (52.96%), ABTS (97.97%), and FRAP (3.16 mmol ET/g) methods. This formulation exhibited enhanced erythroprotective potential, inhibiting hemolysis, photohemolysis, and heat-induced hemolysis. However, viscosity and firm-ness decreased, affecting the texture and appearance. Sensory properties such as color, flavor, aftertaste, texture, and overall acceptance improved with the 10% fucoxanthin-enriched yogurt formulation. These results suggest that nanoliposomes are suitable for carrying fucoxanthin. Their incorporation into food ma-trices is critical to developing functional foods. Regulatory approvals and consumer perceptions regarding nanotechnology-based products must be addressed, emphasizing their safety and health benefits.

7 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
PBPerla de Jesús Balcázar-Vega
Perla de Jesús Balcázar-Vega
FVFridha Viridiana Villalpando-Vargas
Fridha Viridiana Villalpando-Vargas
PBPaola Viridiana Martínez Beltrán
Paola Viridiana Martínez Beltrán
SLSilvia López-Pérez
Silvia López-Pérez
AGAbril Ivett Priscilla Gómez-Guzman
Abril Ivett Priscilla Gómez-Guzman
RVRicardo Vega
Ricardo Vega
Bee venom (BV) contains bioactive peptides with potent antioxidant, anti-inflammatory, and neuroprotective properties, yet its direct therapeutic use is limited by cytotoxicity, instability, and uncontrolled release. This study aimed to develop and evaluate bee venom-loaded nanoliposomes (BV-LN) as an innovative Antioxidant and erythroprotective delivery platform with controlled in vitro release and enhanced gastrointestinal stability for potential applications in neurodegenerative disease management. BV’s antioxidant activity, erythroprotective potential, hemocompatibility, and membrane-stabilizing capacity were systematically assessed, alongside assays for antihemolytic activity against AAPH-induced oxidative hemolysis. BV-LN were synthesized via thin-film hydration and extensively characterized for encapsulation efficiency (84.43 ± 2.26%), water solubility (1.83 µg/mL), centrifugal stability (94.13 ± 3.53%), morphological integrity, and thermal/structural properties (XRD, DSC). Simulated digestion tests confirmed gradual peptide release under gastric and intestinal conditions. Results highlight BV’s strong antioxidant activity (≈70% DPPH inhibition) and marked erythroprotective effects, including >98% hemocompatibility at safe concentrations and significant membrane stabilization under heat and osmotic stress. Encapsulation in nanoliposomes slightly modulated immediate radical scavenging but enhanced safety by preventing excessive hemolysis and enabling controlled melittin release. The robust nanoliposomal structure, driven by peptide–phospholipid hydrophobic anchoring and cholesterol-mediated bilayer ordering, ensured stability under mechanical and digestive stress. This research is highly innovative as it pioneers BV encapsulation for neuroprotective nutraceutical applications, offering a safe, sustained-release platform that could mitigate oxidative stress and inflammation, key drivers of disorders like epilepsy, Alzheimer’s, and Parkinson’s. BV-LN demonstrate strong potential as next-generation carriers for functional foods or therapeutic formulations targeting neurodegenerative diseases, warranting further in vitro validation and translational studies.